TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Period	Debt/Equity
2016-12-31	0.53
2017-12-31	0.45
2018-12-31	2.48
2019-12-31	3.22
2020-12-31	0.20
2021-12-31	0.60
2022-12-31	2.30
2023-12-31	1.05
2024-12-31	1.60
2025-12-31	0.64

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TGTX	$54.40	+2.22%	3.95M
3
4
5

TG Therapeutics Inc. (TGTX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get TG Therapeutics Inc. Data in Excel

More TGTX Financial Data